Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SREEDHAR MANDAYAM

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1225051048
CMS profile
55677
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$146,326.93

210 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 5 of 5; records 201–210 of 210 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SREEDHAR MANDAYAM

NPI 1225051048 · CMS profile ID 55677

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–210 of 210 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1225051048?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SREEDHAR MANDAYAM, NPI 1225051048, CMS profile ID 55677. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–210 of 210 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1225051048?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SREEDHAR MANDAYAM, NPI 1225051048, CMS profile ID 55677. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–210 of 210 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1225051048?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SREEDHAR MANDAYAM, NPI 1225051048, CMS profile ID 55677, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–210 of 210 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1225051048?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

210 matching records · $146,326.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 210 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–210 of 210.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AMAG Pharmaceuticals, Inc. $2.9802/14/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698527955 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $1,742.0002/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709108235 CMS
AstraZeneca Pharmaceuticals LP $35.3402/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685906755 CMS
Allergan Inc. $27.0902/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670763863 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $80.2502/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709108233 CMS
Mallinckrodt Enterprises LLC $1,700.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704760219 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $274.0001/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709108231 CMS
Horizon Therapeutics plc $30.7201/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691437559 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $24.9001/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696054993 CMS
Amgen Inc. $29.3501/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663057583 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $146,326.93 210
PY2020 $56,925.22 69
PY2021 $59,487.65 75
PY2022 $123,719.24 165
PY2023 $147,234.75 201
PY2024 $124,548.89 203
PY2025 $94,217.69 169

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,127,970.53 107
PY2024 Principal investigator $895,420.04 111
PY2023 Recipient $1,102.18 5
PY2023 Principal investigator $1,491,067.06 536
PY2022 Principal investigator $892,861.29 510
PY2021 Principal investigator $376,074.08 272
PY2020 Recipient $940.00 1
PY2020 Principal investigator $318,747.22 133
PY2019 Principal investigator $116,318.40 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

107 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $8,300.00 12/15/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114022
Principal investigator 1 BeOne Medicines USA, Inc. $5,276.00 11/25/2025 Non-covered Recipient Entity
Prolato Clinical Research Center
A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy No dispute reported 06/30/2026 1190341949
Principal investigator 1 AstraZeneca UK Limited $19,090.00 11/19/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) No dispute reported 06/30/2026 1185546055
Principal investigator 1 SANOFI US SERVICES INC. $14,700.00 11/17/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114011
Principal investigator 1 Novartis Pharmaceuticals Corporation $13.46 11/15/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1190310863
Principal investigator 1 Novartis Pharmaceuticals Corporation $15.74 11/15/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) No dispute reported 06/30/2026 1190310865
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,172.80 11/12/2025 Non-covered Recipient Entity
PROVECTA RESEARCH NETWORK LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223288289
Principal investigator 1 SANOFI US SERVICES INC. $4,245.00 11/10/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114001
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $32,855.90 10/29/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER KIRBY DR
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy No dispute reported 06/30/2026 1214124500
Principal investigator 1 BeOne Medicines USA, Inc. $8,732.00 10/28/2025 Non-covered Recipient Entity
Prolato Clinical Research Center
A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy No dispute reported 06/30/2026 1190341946
Principal investigator 1 SANOFI US SERVICES INC. $8,845.00 10/20/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113992
Principal investigator 1 AstraZeneca UK Limited $54,332.16 10/10/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) No dispute reported 06/30/2026 1185546045
Principal investigator 1 Novartis Pharmaceuticals Corporation $423,000.67 10/08/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy Receiving Iptacopan on Top of Supportive Care No dispute reported 06/30/2026 1190309966
Principal investigator 1 Novartis Pharmaceuticals Corporation $19.74 10/08/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190310867
Principal investigator 1 Calliditas Therapeutics US Inc. $1,511.11 10/07/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Nef-403 No dispute reported 06/30/2026 1235023486
Principal investigator 1 Calliditas Therapeutics US Inc. $1,250.16 10/07/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Nef-403 No dispute reported 06/30/2026 1235023504
Principal investigator 1 GENZYME CORPORATION $4,817.00 09/29/2025 Non-covered Recipient Entity
Prolato Research Llc
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226113981
Principal investigator 1 SANOFI US SERVICES INC. $24,200.00 09/29/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113987
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,062.50 09/10/2025 Non-covered Recipient Entity
PROVECTA RESEARCH NETWORK LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223285285
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,995.00 09/10/2025 Non-covered Recipient Entity
PROVECTA RESEARCH NETWORK LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223285287
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,822.50 09/10/2025 Non-covered Recipient Entity
PROVECTA RESEARCH NETWORK LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223285289
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,900.00 09/02/2025 Non-covered Recipient Entity
PROVECTA RESEARCH NETWORK LLC
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition No dispute reported 06/30/2026 1223284741
Principal investigator 1 SANOFI US SERVICES INC. $39,400.00 08/25/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113972
Principal investigator 1 Novo Nordisk AS $450.00 08/22/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
NN9535-4662 No dispute reported 06/30/2026 1213709529
Principal investigator 1 Novo Nordisk AS $593.74 08/22/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
NN9535-4662 No dispute reported 06/30/2026 1213827883
Principal investigator 1 Calliditas Therapeutics US Inc. $4,723.44 08/12/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Nef-403 No dispute reported 06/30/2026 1235023466
Principal investigator 1 SANOFI US SERVICES INC. $20,800.00 08/04/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113944
Principal investigator 1 SANOFI US SERVICES INC. $1,375.00 08/04/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113949
Principal investigator 1 Amgen Inc. $4,050.00 08/01/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC PROLATO CLINICAL RESEARCH CENTER
A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases No dispute reported 06/30/2026 1246646864
Principal investigator 1 Hoffmann-La Roche Limited $675.00 07/18/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639076
Principal investigator 1 Hoffmann-La Roche Limited $202.50 07/18/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639079
Principal investigator 1 Hoffmann-La Roche Limited $623.10 07/18/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639083
Principal investigator 1 SANOFI US SERVICES INC. $4,515.00 07/14/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113928
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,191.11 07/09/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) No dispute reported 06/30/2026 1190310142
Principal investigator 1 SANOFI US SERVICES INC. $16,512.00 07/02/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113918
Principal investigator 1 SANOFI US SERVICES INC. $26,370.00 07/02/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113936
Principal investigator 1 Novo Nordisk AS $20,688.72 06/25/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
NN9535-4662 No dispute reported 06/30/2026 1213734214
Principal investigator 1 Novo Nordisk AS $4,025.00 06/25/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
NN9535-4662 No dispute reported 06/30/2026 1213803996
Principal investigator 1 Novartis Pharmaceuticals Corporation $210,958.90 06/23/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy Receiving Iptacopan on Top of Supportive Care No dispute reported 06/30/2026 1190310138
Principal investigator 1 Travere Therapeutics, Inc. $1,000.80 06/23/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244185953
Principal investigator 1 Hoffmann-La Roche Limited $467.50 06/18/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639059
Principal investigator 1 Hoffmann-La Roche Limited $2,025.00 06/18/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639064
Principal investigator 1 Hoffmann-La Roche Limited $623.10 06/18/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639068
Principal investigator 1 Hoffmann-La Roche Limited $59.40 06/18/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639072
Principal investigator 1 Travere Therapeutics, Inc. $44.00 06/16/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244186887
Principal investigator 1 Travere Therapeutics, Inc. $313.00 06/16/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244186895
Principal investigator 1 Travere Therapeutics, Inc. $300.00 06/16/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244186902
Principal investigator 1 Travere Therapeutics, Inc. $39.00 06/16/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244186906
Principal investigator 1 Travere Therapeutics, Inc. $125.00 06/16/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244186910
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,950.00 06/12/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190310837
Principal investigator 1 Calliditas Therapeutics US Inc. $15,000.03 06/04/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Nef-403 No dispute reported 06/30/2026 1235023442
Principal investigator 1 BeOne Medicines USA, Inc. $7,037.90 06/03/2025 Non-covered Recipient Entity
Prolato Clinical Research Center
A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy No dispute reported 06/30/2026 1190339034
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,000.00 06/03/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) No dispute reported 06/30/2026 1190310831
Principal investigator 1 SANOFI US SERVICES INC. $9,782.12 05/27/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113869
Principal investigator 1 SANOFI US SERVICES INC. $30,542.00 05/27/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113874
Principal investigator 1 SANOFI US SERVICES INC. $19,468.24 05/19/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113880
Principal investigator 1 Travere Therapeutics, Inc. $126.00 05/16/2025 Non-covered Recipient Entity
Prolato Research LLC
DUPLEX study in FSGS No dispute reported 06/30/2026 1244186891
Principal investigator 1 Travere Therapeutics, Inc. $500.00 05/16/2025 Non-covered Recipient Entity
Prolato Research LLC
DUPLEX study in FSGS No dispute reported 06/30/2026 1244186898
Principal investigator 1 Novo Nordisk AS $900.00 04/23/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
NN9535-4662 No dispute reported 06/30/2026 1213752638
Principal investigator 1 Novo Nordisk AS $1,875.00 04/23/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
NN9535-4662 No dispute reported 06/30/2026 1213812549
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,597.15 04/18/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases No dispute reported 06/30/2026 1190310130
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,346.60 04/08/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190310150
Principal investigator 1 Novo Nordisk AS $2,630.00 03/31/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
NN9535-4662 No dispute reported 06/30/2026 1213710042
Principal investigator 1 Novo Nordisk AS $675.00 03/31/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
NN9535-4662 No dispute reported 06/30/2026 1213743224
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,083.15 03/26/2025 Non-covered Recipient Entity
MD ANDERSON CANCER CENTER UNIVERSITY OF TEXAS
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study) No dispute reported 06/30/2026 1190306949
Principal investigator 1 SANOFI US SERVICES INC. $18,616.00 03/17/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113832
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,020.00 03/11/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy Receiving Iptacopan on Top of Supportive Care No dispute reported 06/30/2026 1190309982
Principal investigator 1 Alexion Pharmaceuticals, Inc. $25,770.70 03/06/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) No dispute reported 06/30/2026 1185546047
Principal investigator 1 Travere Therapeutics, Inc. $1,154.00 03/03/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244183750
Principal investigator 1 Travere Therapeutics, Inc. $740.10 03/03/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244183754
Principal investigator 1 Travere Therapeutics, Inc. $1,154.00 03/03/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244183758
Principal investigator 1 Travere Therapeutics, Inc. $1,154.00 03/03/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244183762
Principal investigator 1 SANOFI US SERVICES INC. $32,490.50 02/24/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113819
Principal investigator 1 Amgen Inc. $4,826.25 02/21/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Effect of Pegloticase on reduction of Uric Acid in patients with Tumor Lysis Syndrome: A Pilot Pragmatic Randomized Clinical Trial No dispute reported 06/30/2026 1246638184
Principal investigator 1 BeiGene USA, Inc. $5,960.00 02/11/2025 Non-covered Recipient Entity
Prolato Research LLC
A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy No dispute reported 06/30/2026 1190320504
Principal investigator 1 GENZYME CORPORATION $22,415.00 02/04/2025 Non-covered Recipient Entity
Prolato Research Llc
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226113837
Principal investigator 1 AstraZeneca UK Limited $35,544.90 02/03/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185546053
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,422.50 01/28/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190310835
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $147,615.82 01/27/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER KIRBY DR
A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease No dispute reported 06/30/2026 1214125070
Principal investigator 1 Alexion Pharmaceuticals, Inc. $9,713.50 01/23/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) No dispute reported 06/30/2026 1185546049
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,653.50 01/22/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases No dispute reported 06/30/2026 1190310132
Principal investigator 1 SANOFI US SERVICES INC. $30,003.30 01/21/2025 Non-covered Recipient Entity
Prolato Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113810
Principal investigator 1 Novartis Pharmaceuticals Corporation $67.30 01/15/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1190310140
Principal investigator 1 Novartis Pharmaceuticals Corporation $43.50 01/15/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190310152
Principal investigator 1 Hoffmann-La Roche Limited $59.40 01/08/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639037
Principal investigator 1 Hoffmann-La Roche Limited $2,295.00 01/08/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639042
Principal investigator 1 Hoffmann-La Roche Limited $130.00 01/08/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639046
Principal investigator 1 Hoffmann-La Roche Limited $405.00 01/08/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639050
Principal investigator 1 Hoffmann-La Roche Limited $1,511.00 01/08/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211639055
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,500.00 01/07/2025 Non-covered Recipient Entity
PROLATO RESEARCH LLC
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1190309984
Principal investigator 1 Travere Therapeutics, Inc. $189.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244183618
Principal investigator 1 Travere Therapeutics, Inc. $171.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244183621
Principal investigator 1 Travere Therapeutics, Inc. $600.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
DUPLEX study in FSGS No dispute reported 06/30/2026 1244183624
Principal investigator 1 Travere Therapeutics, Inc. $83.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244183628
Principal investigator 1 Travere Therapeutics, Inc. $700.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244183632
Principal investigator 1 Travere Therapeutics, Inc. $200.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
DUPLEX study in FSGS No dispute reported 06/30/2026 1244183636
Principal investigator 1 Travere Therapeutics, Inc. $100.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244183640
Principal investigator 1 Travere Therapeutics, Inc. $150.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
DUPLEX study in FSGS No dispute reported 06/30/2026 1244183644
Principal investigator 1 Travere Therapeutics, Inc. $300.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244183648
Principal investigator 1 Travere Therapeutics, Inc. $125.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
DUPLEX study in FSGS No dispute reported 06/30/2026 1244183652
Principal investigator 1 Travere Therapeutics, Inc. $88.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244186782
Principal investigator 1 Travere Therapeutics, Inc. $63.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
DUPLEX study in FSGS No dispute reported 06/30/2026 1244186786
Principal investigator 1 Travere Therapeutics, Inc. $313.00 01/07/2025 Non-covered Recipient Entity
Prolato Research LLC
PROTECT Study in IgA Nephropathy No dispute reported 06/30/2026 1244186790
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $201,932.15 01/06/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER KIRBY DR
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3) No dispute reported 06/30/2026 1214124198
Principal investigator 1 AstraZeneca UK Limited $25,315.00 01/03/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185546051
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $190,210.82 01/02/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER KIRBY DR
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) No dispute reported 06/30/2026 1214124786
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $170,345.05 01/01/2025 Non-covered Recipient Entity
PROLATO CLINICAL RESEARCH CENTER IBN SINA COMMUNITY N. SHEPHERD MEDICAL DENTAL
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1214123336